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Tolerability of induction chemotherapy dosing practices in acute 
myeloid leukemia patients 
Kaylene M. Peric 
David J. Reeves 
 
Abstract 
For patients with high body surface areas (BSA), differing chemotherapy dosing strategies have 
been utilized in attempts to reduce toxicity. In a retrospective evaluation, we compared the effects 
of chemotherapy dosing in acute myeloid leukemia patients with high BSA (>2 m2) who received 
capped doses (n = 12) to those who received uncapped doses (n = 24), and to patients with 
BSA ≤ 2 m2 (n = 42). There were no statistically significant differences among groups 
(BSA ≤ 2 m2, BSA > 2 m2 capped, and BSA > 2 m2 uncapped) in the incidences of febrile 
neutropenia (85.7, 66.7, and 75.0%, respectively, p = 0.29), bacteremia (19.0, 8.3, and 16.7%, 
respectively, p = 0.68), mucositis (42.8, 50.0, and 41.7%, respectively, p = 0.88) or 
nausea/vomiting (47.6, 33.3, and 37.5, respectively, p = 0.57). Results suggest delivery of 
unadjusted chemotherapy based on actual body weight is likely safe in hematological 
malignancies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
Chemotherapy agents are known to have narrow therapeutic indices, where a small difference in 
dose could potentially lead to poor treatment outcomes or increased toxicity [1], [2], [3] and [4]. 
This makes dose selection challenging, especially since many of the variable patient-related factors 
affecting the metabolism and clearance of these drugs are difficult to predict [3], [5] and [6]. It is 
often assumed that larger patients require higher doses than smaller patients to provide similar 
drug concentrations and outcomes [4]. Body surface area (BSA) has traditionally been and remains 
the most frequent measure used to determine chemotherapy doses [7], [8] and [9]. This method of 
dosing leads to difficulties when heights and/or weights are at extremes [3] and [6]. Given the rise 
in prevalence of obesity worldwide over the past few decades [10], selecting doses in this group is 
a common struggle due to concerns for potential toxicity associated with larger doses of 
chemotherapy when actual body weight is used to determine dosing. Thus, various dosing 
strategies for the obese population have been utilized amongst practicing physicians and 
institutions [11], [12] and [13]. Some of these include use of an adjusted body weight, ideal body 
weight, or capping the BSA at 2 m2[4], [11], [12], [13], [14] and [15]. As result of this empiric 
weight modification, up to 40% of obese patients have received intentionally reduced 
chemotherapy dosages in an attempt to reduce the potential toxic effects [16]. 
In an attempt to clarify dosing strategies for clinicians, the American Society of Clinical Oncology 
(ASCO) developed a clinical guideline in April 2012, recommending the use of full-dose 
chemotherapy based on actual body weight for obese cancer patients specifically when the 
treatment goal is cure of the disease [17]. However, the guideline recommendations are based on 
studies in solid tumor malignancies and did not include obese patients receiving therapy for 
hematological malignancies. Patient weight in the leukemic population has been assessed in 
multiple studies in terms of impact on survival and toxicity; however, empiric dosing strategies to 
mitigate patient risk for toxicity (dose capping) has only been evaluated in one prior study [18], 
[19], [20] and [21]. The purpose of this study was to evaluate chemotherapy dosing in adult acute 
myeloid leukemia (AML) patients receiving induction treatment and determine if there are 
differences in toxicities when doses in patients with BSA > 2 m2 are empirically capped, compared 
to when they are not capped, and to patients with BSA values ≤2 m2. 
2. Methods 
2.1. Study patients 
This retrospective, single center study was approved by the local Institutional Review Board. Adult 
patients with a diagnosis of AML that completed standard induction chemotherapy consisting of 
an anthracycline (idarubicin or daunorubicin) daily for 3 days in combination with continuous 
infusion cytarabine for 7 days between January 2008 and August 2013 were included in the study. 
Patients whom received radiation therapy or were pregnant during therapy were excluded. 
2.2. Data collection and analysis 
Demographic and clinical characteristics were collected from the electronic health record for all 
eligible patients, which included age, sex, height, weight, and calculated BSA value. 
Chemotherapy agents and their respective doses administered, in addition to whether G-CSF was 
used during patients’ hospital stay were also identified. 
The following adverse effects were collected: episodes of febrile neutropenia, documented 
mucositis, documented bacteremia, and documented nausea and vomiting. Additional outcomes 
such as day of neutrophil recovery (ANC > 500 cell/mcL) post chemotherapy, length of hospital 
stay, and attainment of complete remission post induction chemotherapy as defined by the 
International Working Group (IWG) criteria (bone marrow blasts < 5%, ANC > 1000 mcL−1, 
platelet count > 100,000 mcL−1), were also collected [22]. 
BSA values were calculated based on patient height and weight using the Mosteller formula, 
([height (cm) × weight (kg)]/3600)1/2[9]. Patients were categorized into three groups based on their 
calculated BSA and the BSA utilized to dose the patient: those with BSA > 2 m2 whom received 
empirically capped chemotherapy doses (capped group), those with BSA > 2 m2 whom received 
full actual body weight calculated doses (uncapped group), and those with BSA ≤ 2 m2. The 
BSA > 2 m2 capped group was compared to both the BSA > 2 m2 uncapped group, and to the 
BSA ≤ 2 m2 group. The BSA > 2 m2 uncapped group was also compared to the BSA ≤ 2 m2 group. 
2.3. Outcome measures 
The primary end point was the overall incidence of adverse effects during admission, which 
included: occurrence of febrile neutropenia, documented mucositis, documented bactermia, and 
documented episodes of nausea or vomiting. Secondary endpoints were time (days) to neutrophil 
recovery (ANC > 500 cells/mcL) after the start of chemotherapy, length of hospital stay, and 
complete remission following induction chemotherapy. 
2.4. Statistical methods 
Continuous variables between groups were compared using Student's t-test (or non parametric 
Mann–Whitney U tests, dependent upon the parametric nature of the data). Categorical data was 
compared between groups using a Fisher's exact test or a Pearson chi-square test, as appropriate. 
These analyses were performed using SPSS 21.0 (Statistical Package for the Social Sciences, 
Chicago, IL). A two sided p-value <0.05 was considered significant. Univariate comparisons on 
demographic and clinical variables were made to assess the comparability between the three 
groups. Incidences of adverse effects were analyzed univariately using Fisher's exact tests. Binary 
logistic regression analyses were used to obtain adjusted odds ratios of the significant predictors 
of adverse events and the attainment of complete remission following induction chemotherapy. 
Predictors accounted for in the regression included BSA, dosing strategy (capped/uncapped), sex, 
age, history of prior chemotherapy, receipt of granulocyte-colony stimulating factor and 
chemotherapy agent (daunorubicin/idarubicin). Time to neutrophil recovery and hospital lengths 
of stay were analyzed using Kaplan Meier survival analysis and Cox regression. 
 
 
 
3. Results 
3.1. Baseline and treatment characteristics 
Of the 78 patients included in the evaluation, 42 had a BSA ≤ 2 m2, 24 had a BSA > 2 m2 and 
received uncapped actual body weight (ABW) calculated doses, and 12 had BSA values >2 m2 
and received capped doses. Patient demographics and treatment characteristics are provided in 
Table 1. Excluding the expected differences in average weight, height and BSA, there were no 
significant differences in patient characteristics between the groups except for gender. A higher 
proportion of patients were male in the BSA > 2 m2 groups. The average age of all evaluated 
patients was 56.5 years and few patients (10.3%) had previous chemotherapy exposure. All 
patients completed standard induction chemotherapy with an anthracycline and cytarabine. The 
type of anthracycline agent received and dosages (daunorubicin, 30–90 mg/m2; idarubicin, 
12 mg/m2; cytarabine 100–200 mg/m2) were not different among the groups. The actual capped 
dose administered to patients with a BSA > 2 was on average 10.5% lower for idarubicin, 13.3% 
lower for daunorubicin, and 11.4% lower for cytarabine then they would have been had their doses 
been uncapped. 
 
Table 1. Baseline and treatment characteristics. 
 BSA ≤ 2 m
2 
(n = 42) 
BSA > 2 m2 
capped (n = 12) 
BSA > 2 m2 
uncapped (n = 24) 
p-
Value 
Mean age (years) 58.9 53.8 53.7 0.61 
Male, n (%) 15 (35.7) 8 (66.7) 18 (75) 0.005 
Mean BSA, m2 (range) 1.78 (1.45–1.98) 2.25 (2.05–2.85) 2.20 (2.02–2.73) 0.001
* 
Mean weight (kg) 70.3 107.9 100.6 0.001* 
Mean height (cm) 165.2 176.8 178.6 0.001* 
Previous chemotherapy exposure, n 
(%) 3 (7.1) 2 (16.2) 3 (12.5) 0.57 
Receipt of granulocyte colony 
stimulating factor (G-CSF), n (%) 12 (28.6) 1 (8.3) 9 (37.5) 0.19 
Median daunorubicin dosage (mg/m2) 
[IQR] 60 [45.0] 52.5 [32.5] 60 [20.0] 0.98 
Median idarubicin dosage (mg/m2) 
[IQR] 12 [0] 12 [0] 12 [0] 1.00 
Median cytarabine dosage (mg/m2) 
[IQR] 100 [100] 100 [100] 100 [100] 0.74 
BSA: body surface area, IQR: interquartile range. 
*Statistically significant difference between BSA ≤ 2 m2 and BSA > 2 m2 groups. No statistically 
significant difference between BSA > 2 capped and BSA > 2 uncapped groups in BSA (p = 0.36), weight 
(p = 0.21), and height (p = 0.54). 
 
 
3.2. Outcomes 
There were no significant differences in rates of chemotherapy related adverse effects among 
patients with BSA ≤ 2 m2, BSA > 2 m2 that received capped doses, and BSA > 2 m2 that received 
uncapped doses (Table 2). The most common adverse effect was febrile neutropenia, which 
occurred in 85.7%, 66.7% and 75.0% (p = 0.29) of patients, respectively. Thirteen of the 78 
patients (16.7%) had documented bacteremia during their admission with no significant difference 
in incidence among the groups (19.0%, 8.3%, 16.7; p = 0.68). The rates of documented mucositis 
were similar between groups (p = 0.88), affecting 42.8% of patients in the BSA ≤ 2 m2 group, 
50.0% in the BSA > 2 m2 capped group, and 41.7% in the BSA > 2 m2 uncapped group. The 
reported incidence of nausea and/or vomiting was 47.6%, 33.3%, and 37.5%, respectively 
(p = 0.57). 
 
Table 2. Incidence of adverse effects. 
 BSA ≤ 2 m
2 
(n = 42) 
BSA > 2 m2 capped 
(n = 12) 
BSA > 2 m2 uncapped 
(n = 24) 
p-
Value 
Febrile neutropenia, n (%) 36 (85.7) 8 (66.7) 18 (75.0) 0.29 
Nausea/vomiting, n (%) 20 (47.6) 4 (33.3) 9 (37.5) 0.57 
Mucositis, n (%) 18 (42.8) 6 (50.0) 10 (41.7) 0.88 
Bacteremia, n (%) 8 (19.0) 1 (8.3) 4 (16.7) 0.68 
Median time to ANC > 500 
cells/mcL (days) 25.5 24.5 29.5 0.48 
Median length of hospitalization, 
days 31.5 27.5 35.0 0.34 
 
Complete remission (CR)     
Number evaulable 37 10 22  
CR, n (%) 17 (45.9) 7 (70.0) 11 (50%) 0.4 
BSA: body surface area, ANC: absolute neutrophil count, std. dev: standard deviation. 
 
The mean time to neutrophil recovery was longest for the patients that received uncapped doses, 
but not significantly different (p = 0.48) among the three groups (Fig. 1). It took a median of 25.5 
days for patients with BSA ≤ 2 m2 to recover their neutrophils compared to 24.5 days for those 
with BSA > 2 m2 that received capped doses and 29.5 days for those with BSA > 2 m2 that received 
uncapped doses. Median length of hospital stay did not significantly differ among the three groups 
(31.5 days, 27.5 days, 35.0 days, respectively, p = 0.34). 
 Fig. 1. Days to neutrophil recovery post induction chemotherapy. 
 
Based on the post-induction analysis of complete remission (CR), there was no significant 
difference in the incidence of CR among all the groups. Of the 37 patients in the BSA ≤ 2 m2 group 
evaluable for response, 17 (45.0%) achieved a CR. Similarly, 50.0% of patients with BSA > 2 m2 
that received uncapped doses (22 evaluable patients) and 70.0% of those that received capped 
doses (10 evaluable patients) achieved a CR. In total, 5 patients experienced early death (prior to 
assessment of response). 
 
Utilizing multivariate analysis, BSA and dosing strategy (capped/uncapped) were not found to be 
significantly associated with toxicity rates (febrile neutropenia, bacteremia, mucositis, 
nausea/vomiting) or post-induction complete remission rate. Age was the only significant predictor 
of nausea/vomiting (odds ratio 0.96, 95% CI 0.92–0.99, p = 0.02). 
 
4. Discussion 
 
As the prevalence of obesity continues to increase worldwide [10], clinicians will likely encounter 
a greater proportion of cancer patients with high BSA values. Determining the most appropriate 
strategy for dosing chemotherapy in this population is important to ensure effective treatment 
while avoiding unnecessary toxicities. 
 
Much of the current knowledge of dosing practices and chemotherapy toxicity effects in obesity 
is based on evidence in breast cancer. However, a few studies are available in the leukemic 
population in which body weight has been reported to effect outcomes. A study of 97 adults with 
AML over the age of 60 years investigated the association between baseline BMI and overall 
survival [19]. Patients with a BMI greater than 30 had a lower hazard ratio for mortality compared 
to those with a BMI less than 25 (HR 2.14; 95% CI 1.21 to 3.77). Patients in this study were dosed 
based on actual body weight without any dose reductions in the obese population. Similarly, a 
study of 1974 adult patients with AML showed CR rates were higher with increasing BMI (OR 
1.03, p = 0.004) and that there was no association between toxicity and BMI [20]. Patients were 
treated with doses based on actual BSA (one patient received treatment based on ideal body 
weight). In yet another study (n = 247), the toxicity and efficacy of actual body weight based 
chemotherapy doses were compared amongst underweight/normal (BMI < 18.5–24.9 kg/m2), 
overweight (BMI 25–29 kg/m2), and obese (BMI > 30 kg/m2) AML patients that received standard 
induction treatment [18]. Results showed no significant differences in toxicity, including days to 
neutrophil recovery, incidence of documented bacteremia and heart failure among normal, 
overweight and obese patient groups. In addition, complete remission rates were also similar 
among the groups. Authors concluded that use of full actual body weight based doses is justified 
even at extremes of weight. Overall, these assessments were based on patients who received non-
dose reduced chemotherapy regimens and excluded those with empirically adjusted doses. 
 
One study investigating the impact of obesity on the efficacy and toxicity of induction 
chemotherapy in AML patients (n = 63) did describe the impact of dose reduction in the obese 
population [21]. Obesity was defined as ≥30% above ideal body weight. Seven of the 21 obese 
patients received a dose reduction (1 was reduced for renal impairment, 4 used an adjusted weight 
BSA, and 2 capped the BSA at 2). No differences were identified in toxicity between those 
receiving a dose reduction and those receiving unreduced doses based on actual body weight. 
Additionally, there was no association in the total population between obesity and toxicity, 
including neutrophil recovery by 30 days (OR 1.11, p = 0.43) and platelet recovery by 30 days 
(OR 1.12, p = 0.36). 
 
Our evaluation showed similar results, although patients were analyzed based on their BSA and 
respective dosing strategy used, rather than BMI or precent above ideal body weight. We found 
no significant differences in the incidences of any of the evaluated chemotherapy related adverse 
effects, time to neutrophil recovery, or lengths of hospitalization among patients with BSA ≤ 2 m2, 
those with BSA > 2 m2 that received uncapped doses, and those with BSA > 2 m2 that received 
intentionally capped doses. Additionally, assessment of response to determine efficacy of the 
received induction therapy demonstrated no differences in rates of CR after bone marrow recovery 
between the groups. 
 
Interestingly, patients with BSA ≤ 2 m2 experienced a greater incidence (though non-significant) 
of febrile neutropenia, nausea/vomiting, and documented bacteremia than patients with 
BSA > 2 m2 regardless of dosing strategy used. Similar results have been shown in previous studies 
performed in breast cancer patients suggesting larger patients may be underdosed even with full, 
actual body weight based doses [1] and [13]. 
 
Overall, our patient population recovered their neutrophils a few days sooner than the previous 
study of AML patients (27.3 vs 33.0 days, respectively) [20]. Although not statistically significant, 
it took slightly longer to recover neutrophil counts for those patients that received uncapped doses 
(29.6 days) implying a possible greater myelotoxic effect compared to those who received capped 
doses and those with BSA ≤ 2 m2 (23.6 and 26.7 days), respectively. However, there was no 
correlation with neutrophil recovery time and average length of hospitalization as patients in the 
BSA ≤ 2 m2 group recovered their counts sooner than the uncapped group, but had a non-
significant longer hospital stay. 
 
Limitations include the retrospective design of the study as some patients had incomplete and/or 
missing data if they received follow-up outside the institution. Though analysis of the data showed 
that there were no significant differences between groups, the results may be limited by the small 
sample size and may lack the power to detect more minute differences. Most importantly, 
prognostic factors were not taken into account when assessing response, making efficacy difficult 
to assess and compare across groups. In addition, the primary outcome was the incidence of 
adverse effects, which relied on physician interpretation and documentation in the medical record. 
 
 
5. Conclusion 
 
The use of ABW based doses in patients with BSA > 2 m2 was not associated with an increase in 
toxicity as there were no significant differences in the incidence of adverse effects among the 
BSA > 2 m2 capped, BSA > 2 m2 uncapped, and BSA ≤ 2 m2 groups. Attempts to reduce toxicity 
by empirically reducing chemotherapy doses for patients with high BSA values may not be 
justified as no significant benefit was seen in regard to toxicity or neutrophil recovery in patients 
with BSA > 2 m2 who received capped doses. These results further support the safety of ASCO 
recommendations for the use of uncapped/unadjusted chemotherapy doses in the hematological 
malignancy setting. 
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